[A trial of the use of sandostatin in patients with chronic pancreatitis].
Out of 15 patients with chronic pancreatitis (CP) treated with sandostatin, 8 patients demonstrated a complete and 6 partial response. One patient did not respond. Pain relief occurred in all of them. Side effects were registered in 3 patients (doughy stools 4 times a day throughout treatment). Normal blood levels of pancreatic enzymes, insulin secretion, parameters of blood inhibitory system did not change much because of sandostatin administration, whereas hypercoagulation got diminished. Rat experiments have revealed a trend to trypsin lowering in tissues of unaffected pancreas and more intensive inhibition of active trypsin by tissue inhibitors.
D000328:Adult; D000437:Alcoholism / Q000150:complications; D000818:Animals; D002764:Cholecystitis / Q000150:complications; D002908:Chronic Disease; D004353:Drug Evaluation, Preclinical; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006728:Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D010195:Pancreatitis / Q000188:drug therapy* / Q000209:etiology; D051381:Rats
D005765:Gastrointestinal Agents; D006728:Hormones; D015282:Octreotide
Opyt primeneniia sandostatina u bol'nykh khronicheskim pankreatition.